The Fund Grade · free · no account needed
What grade does HFCVX get?
Morningstar rates funds on what they returned. We grade them on where their money sits today: how much of the book overlaps with the converged buys of the top specialist stock pickers.
Fundprints Fund Grade · as of 2026-10-01
Hennessy Cornerstone Value Fd Inv Cl
#277 of 500 graded active funds · value · large segment peer group
The point · specialist footprint
HFCVX puts more of its book behind proven specialists than 61% of graded funds.
Bottom 20%
Bottom 40%
Middle
● Top 40%
Top 20%
That has mattered: over the past 2.7 years, funds on this rung beat bottom-rung funds by about 3.8% per quarter, and beat the S&P in 43% of fund-quarters versus their 22%. The evidence argues this fund earns its seat.
10,000+ funds tracked · the graded specialists among them drive every read
3 funds in the same segment carry an A. Members see the names and what they charge. See the alternatives →
The grade scores this fund's specialist share, the slice that overlaps what the top 1% of proven funds are building. We ignore index ballast and names outside our edge on purpose: that slice is small, and it's what decides the outcome.
HFCVX vs the Honor Roll · share card ↗Conviction exposure
31.5%
of the book in specialist-converged names
Late-stage weight
24.1%
of the book in Crowded or Fading names
Active share
92.3%
how far it strays from the index
The best grades have beaten the worst by about +5% a year since we began grading. The gap held in 9 out of 10 months. Measured on filings as they were published, no hindsight.
Inside the book: top names by stage · as of 2026-10-20
We email you the day it crosses 50% crowded, and where you stand every month.
Graded monthly from point-in-time filings. A description of where the money sits, not a recommendation. Evidence, not advice.
The read · what to do with it
HFCVX earns a C grade, ranking 277 of 500, with specialist investors holding only 31.5% of the fund. The early conviction calls on VZ, BMY, and C are interesting, but positions in MO, GSK, and PEP are fading, and the fund sits in a segment where three higher graded peers exist.
→ Watch MO, GSK, and PEP closely, as specialists are actively leaving all three positions inside this fund.
→ Compare HFCVX against higher graded funds in the same family and segment before adding more capital to this C rated holding.
Support leaving these positions
Same family, higher grade
Read from today's disclosed book. Evidence, not advice.